Prevalence And Clinical Significance Of Systemic Inflammation In Hfpef And Hfmref
Barry A. Borlaug,Cecile Holse,Mette Holme Jung,A. Michael Lincoff,Sharon Mulvagh,Jacob Stærk-Østergaard,Katherine Tuttle,Mark Petrie
DOI: https://doi.org/10.1016/j.cardfail.2023.10.399
IF: 6.592
2024-01-01
Journal of Cardiac Failure
Abstract:Background Systemic inflammation has been implicated as a potential risk factor for heart failure (HF) with preserved or mildly reduced ejection fraction (HFpEF, HFmrEF), but little is known regarding the prevalence and clinical correlates of systemic inflammation in patients with prevalent HFpEF/HFmrEF. Methods We compared baseline clinical characteristics, laboratory assessments, and vital signs in patients with HFpEF/HFmrEF enrolled in 3 large cardiovascular outcomes trials testing the glucagon like peptide-1 receptor agonist semaglutide, including those with body mass index (BMI) >27 kg/m2 and established cardiovascular (CV) disease (SELECT, NCT03574597), type 2 diabetes (T2D) and chronic kidney disease (CKD; FLOW, NCT03819153), and T2D and atherosclerotic CV disease or CKD (SOUL, NCT03914326). Patients with inflammation (defined as CRP≥2 mg/l) were compared to those without (CRP<2 mg/l) as identified by CRP level at enrollment. Results Of 4457 patients with HF (n=3211 HFpEF, n=1246 HFmrEF), 2340 (53%) had CRP≥2 mg/L. As compared to patients with CRP<2 mg/l, those with elevated CRP were more likely to be women and had greater body mass index (Table). Patients with CRP≥2 mg/l had higher resting heart rate (HR) and systolic blood pressure, poorer kidney function, higher HbA1c, and more severe lipid abnormalities. Prevalence of T2D and microvascular diseases including CKD and neuropathy were higher in those with CRP≥2 mg/l than those with CRP<2 mg/l. CRP was directly correlated with heart rate (ρ=0.157, 95% CI 0.128 to 0.186, p<.0001), suggesting a greater burden of autonomic dysfunction. Conversely, the prevalence of macrovascular CAD and prior myocardial infarction were lower in patients with CRP≥2 mg/l compared to those with CRP<2 mg/l. Findings were similar when analyzing patients with HFpEF and HFmrEF separately. Conclusions Systemic inflammation is present in over half of patients with HFpEF/HFmrEF included in the SOUL, FLOW and SELECT trials and is associated with female sex, higher BMI, metabolic stress, and microvascular disease, features all previously linked to the pathophysiology of HF with preserved or mildly reduced EF, suggesting potential causal relationship. These data support further study into therapies targeting inflammation in HFpEF/HFmrEF.
cardiac & cardiovascular systems